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Abstract: Therapeutic antibodies to programmed death receptor 1 
(PD-1) and its ligand PD-L1 show promising clinical results. Anti-
PD-L1 immunohistochemistry (IHC) may be a biomarker to select 
patients more likely to respond to these treatments. However, the 
development of at least four different therapeutics, each with a dif-
ferent anti-PD-L1 IHC assay, has raised concerns among patholo-
gists and oncologists alike. This article reviews existing data on the 
IHC biomarker aspects of studies using these drugs in non–small-cell 
lung cancer (NSCLC) and considers the challenges ahead, should 
these drug/IHC assay combinations reach routine practice. For each 
the known biomarker assays in development, there is a different 
monoclonal IHC antibody clone, produced by one of two diagnos-
tics companies. Each test requires proprietary staining platforms and 
uses different definitions of a “positive” test for PD-L1 expression, 
on tumor cells and, in one test, also on tumor infiltrating immune 
cells. There are still considerable gaps in our knowledge of the tech-
nical aspects of these tests, and of the biological implications and 
associations of PD-L1 expression in NSCLC, considering heteroge-
neity of expression, dynamic changes in expression, and prognostic 
implications among other factors. The International Association for 
the Study of Lung Cancer Pathology Committee raises the prospect 
of trying not only to harmonize and standardize testing for PD-L1 
by IHC, at least at a technical level, but also, ideally, as a predictive 
marker, to facilitate availability of this test and a promising treatment 
for patients with NSCLC.
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IMMUNE CHECKPOINT INHIBITION:  
A PROMISING THERAPEUTIC STRATEGY  
FOR LUNG CANCER
In the search for effective therapies in patients with lung 
cancer, immune checkpoint inhibitory approaches have shown 
considerable promise.1–4 A number of ligand–receptor interac-
tions, including PD-1/PD-L1 and B7/CTLA-4, seem to switch 
off the immune response in lung cancer, a tumor that in gen-
eral has a high rate of somatic mutations, which may make such 
tumors more immunogenic.5,6 Much of this therapeutic focus in 
lung cancer, particularly in non–small-cell lung cancer (NSCLC), 
has been on interrupting the interaction of programmed death 
receptor-1 (PD-1) and its ligand (PD-L1) between tumor cells 
and immune effectors cells, using monoclonal antibodies against 
PD-L1 or PD-1. In this era of personalized medicine using tar-
geted biological agents, biomarkers predictive of response to 
therapy are central to treatment decision making.
AVAILABLE THERAPIES AND BIOMARKERS
There are a number of therapeutic anti-PD-L1 (e.g., 
MPDL3280A [Roche, Basel, Switzerland] and MEDI-4736 
[Astra Zeneca, London, UK]) or anti-PD-1 (nivolumab 
[Bristol Myers Squibb, New York, NY]) and pembrolizumab 
[Merck, Kenilworth, NJ]) agents at various stages of develop-
ment, and the favored biomarker seems to be the expression 
of PD-L1 assessed by immunohistochemistry (IHC; Fig. 1). 
There are limited data currently available, for these thera-
peutic agents, in lung cancer, in particular in patients with 
advanced NSCLC. Different approaches have been taken to 
PD-L1 IHC assessment, using different diagnostic antibodies 
to assess PD-L1 expression, different technical staining plat-
forms, and different definitions of a “positive” predictive IHC 
stain. In some cases, expression of PD-L1 on immune effec-
tor cells as opposed to, or in combination with, expression in 
tumor cell, has been chosen as the biomarker.
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PROBLEMATIC ISSUES WITH EXISTING DATA
Some of the essential findings so far reported are 
presented in Table 1.7–20 Data are limited and most remain 
unpublished at the time of writing. Depending on defini-
tions, positivity rates for PD-L1 range from 13% to 70%, 
and correlation between biomarker positivity and treatment 
response rates vary from 13% to 83% depending upon the 
biomarker-defined cohort and therapy used. Most studies 
also report significant response rates (3–20%) in PD-L1 IHC 
negative cases. Most of the studies assess PD-L1 expression 
in tumor cells and regard membrane staining as most sig-
nificant. There is variable interpretation of the intensity and 
distribution of staining and variable definition of a positive 
PD-L1 stain ranging from staining of ≥1% to ≥50% of cells 
assessed. In some cases, the test requires at least 100 tumor 
cells to be assessed.
Biomarker Positivity and Response
The value of the chosen biomarker seems to vary 
in terms of predicting a response to therapy, and in some 
cases this also seems to depend on which line of therapy 
for which the immune checkpoint inhibitory agent is given 
(Table 1). The biomarker test may not represent the true 
PD-L1 status of the tumor, either because of heterogeneity 
of expression and sampling error, or because the test sam-
ple predates earlier lines of therapy (see below). In general, 
however, there is a higher response rate in the PD-L1 posi-
tive population compared with the PD-L1 negative group of 
patients, although in some studies this difference is not sig-
nificant. The presence of patients who respond to therapy, 
in the PD-L1 negative cohort, calls into question the value 
of PD-L1 IHC as a predictive biomarker to select a patient 
subgroup for therapy.
Biomarker Thresholds
Determining the threshold that defines a positive, predic-
tive test is a difficult issue. Thresholds may be predetermined, 
before outcome data are known, or as a more useful approach, 
the response data may be used to indicate the threshold that gives 
best discrimination between responders and nonresponders, or 
between patients who do or do not derive significant survival 
benefit from the therapy. It has, however, been noted that tradi-
tional response evaluation criteria in solid tumors for assessing 
tumor response may not be best suited to assessing clinically 
significant responses to immune checkpoint inhibitor therapy, at 
least in a small proportion of the cases. There is then a potential 
trade-off between improving upon the response rates seen in an 
unselected treated population, the acceptability of this response 
rate in an unselected population versus that seen with standard 
of care treatment, and any considerations to maximize the 
population eligible for treatment. In addition, to date, response 
(overall response rate) alone does not seem to be the best way 
to evaluate the benefit of immunotherapy; this is probably better 
captured by progression-free or overall survival data. Finally, if 
very low staining thresholds such as 1% or even 5% of cells are 
chosen, there is a greater risk that scoring will be inconsistent 
and is more likely to reflect inaccurately the patient’s tumor bur-
den overall, because of heterogeneity.
Heterogeneity and Prior Therapy
Limited data suggest that PD-L1 expression is hetero-
geneous, reflected in low thresholds being used to define 
positive staining. Little is understood regarding the relation-
ship between PD-L1 expression in the primary tumor and 
any metastases. Earlier lines of chemotherapy or targeted 
therapy may well induce PD-L1 expression, consequently 
PD-L1 expression in the original “chemo-naive” diagnostic 
FIGURE 1.  Programmed death 
receptor-1 with its ligand (PDL-1) 
immunostaining performed using the 
E1LN3N clone anti-PD-L1 from Cell 
Signaling Technology (Boston) with 
standard detection techniques. A, 
Squamous cell carcinoma showing a 
strong, uniform positive reaction in 
tumor cells. B, Despite being nega-
tive in tumor cells in the center of the 
image, there is a positive reaction in 
macrophages and other immune cells 
in the tumor stroma. C, Most alveolar 
macrophages are positive for PD-L1. 
D, This adenocarcinoma is negative 
for PD-L1. It should be noted that this 
immunohistochemistry clone was not 
used for PD-L1 detection in any of the 
trials discussed in this review.
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sample may not represent the status of the tumor at the 
time that an immune checkpoint inhibitor therapy is intro-
duced. This dynamic property may explain why biomarker 
data have not necessarily predicted responses when some 
of these drugs are given in second or later lines, reflecting 
response rates of 10–20% while the biomarker was nega-
tive in the chemo-naive sample. For most existing data, it 
is not clear whether archival, chemo-naive samples, or new 
samples, taken after chemotherapy, were used for PD-L1 
IHC assessment. we clearly need more data to understand 
properly the meaning and value of PD-L1 IHC as a predic-
tive biomarker.
PD-L1 in Tumor Infiltrating Immune Cells
There is a particular concern about any biomarker test 
that is predicated upon biomarker expression in lymphoid 
or other immune effector cells (tumor infiltrating immune 
cells) rather than tumor cells. Apart from issues around rec-
ognition of these cells in small biopsy or cytology samples, 
there are questions with respect to the relevance of any lym-
phocytes in the sample, as far as a tumor-directed immune 
response is concerned. In small biopsy samples, the patholo-
gist is severely challenged to determine whether a lympho-
cyte population present is reacting to the tumor, i.e., are 
tumor-infiltrating lymphocytes or are bystander lymphoid 
cells native to the tissue where the tumor has developed 
or are they present in the tissue for another reason. Many 
diagnostic samples are so small and disaggregated that it 
is impossible to adequately relate any lymphoid or other 
immune effector cells to the tumor present. For this reason, 
a biomarker test based upon tumor infiltrating immune cells 
would almost certainly rule out lymph node biopsy samples 
and possibly all cytology specimens.
TEST REPRODUCIBILITY AND  
EPITOPE STABILITY
Inevitably, whenever an IHC-based biomarker is consid-
ered, questions arise about the reproducibility of the test, not 
only in technical terms for producing the staining but also in 
interpretation of the test by pathologists. Furthermore, how 
stable are the epitopes detected by the various antibodies, 
which raises issues about the use of stored, pre-cut sections. 
Preanalytical issues such as tissue fixation and processing 
can have a major impact on the outcomes of immunohisto-
chemical reactions,21 and how these might affect the different 
reported PD-L1 IHC tests is not known.
MULTIPLE DRUGS AND MULTIPLE  
BIOMARKER ASSAYS
Notwithstanding the difficulties there may be in deliv-
ering a robust biomarker assessment for PD-L1 IHC, how 
shall the pathology community handle the prospect of mul-
tiple different tests, ostensibly measuring the same biomarker 
that determine the prescription of several different therapeutic 
agents targeting the same molecular mechanism? Our experi-
ence of the development of companion IHC diagnostics sug-
gests that these biomarkers may become available only in the 
form of a prepackaged test kit of reagents. The benefits of not 
only such standardization, but also the associated costs, are 
well understood. However, these kits normally mandate the 
use of a company-specific automated staining platform. Many 
pathology departments may be constrained by available tech-
nology and may not be able to carry out a required test, which 
may lead to low screening rates and patients missing out on 
targeted therapies if access to the drug is predicated on a spe-
cific, and more expensive, test requiring company-specific 
staining platforms.
TABLE 1.  Summary of Published Findings for PD-L1 Immunohistochemistry in Therapeutic Trials
Drug
Biomarker  
Antibody Rx Line
Definition of 
“Positive”a (%) N Positive (%)
Positive Predictive 
Outcome
ORR % IHC 
pos. Cases
ORR % IHC  
neg. Cases Ref.
Nivolumab Dako 28-8 1st ≥5 in >100 cells 59 Yes 31b 10 7,8 f
Nivolumab Dako 28-8 ≥2nd ≥5, ≥1 49, 56 No 15, 13 14, 17 9,10
Nivolumab + 
Ipilimumab
Dako 28-8 1st ≥5 in >100 cells 42 No 19 14 11
Nivolumab Dako 28-8 ≥2nd ≥5 33c Yes 24 14 12 f
Nivolumab 5H1d ≥2nd ≥5, also studied 
TIICs
67 Yes No data  
for lung
No data  
for lung
13
Pembrolizumab Dako 22C3 Any “Strong” ≥50, 
“weak” 1–49
25, 70 Yes, Yes 37, 17 9 14
Pembrolizumab Dako 22C3 1st ≥50, ≥1 ? Yes 47, 26 ? 15
MPDL3280A Roche ventana, SP142 ≥2nd ≥10,e ≥5, ≥1 TIICs 13, 28, 56 Yes 83, 46, 31 18, 18, 20 16–18
MEDI-4736 Roche ventana, SP263 ≥2nd Data not available 41 Yes 25 3 19,20
aExpression in tumor cells unless otherwise stated.
b The 31% figure is for all tumors. The ORR was 37% in nonsquamous tumors and 12% in squamous cases. In PDL-1 negative cases, ORR was 14% in nonsquamous tumors and 
0% in squamous tumors.
cThis study concerned squamous cell carcinomas only.
dThese authors also used the anti-PD-1 monoclonal M3 in their immunohistochemical analysis.
eIHC score 3, ≥10% TIICs positive; IHC score 2–3, ≥5% TIICs positive; IHC score 1–2–3, ≥1% TIICs positive.
f ORR quoted are those actually presented, as opposed to those published in the abstract
IHC, immunohistochemistry; TIICs, tumor infiltrating immune cells; ORR, overall response rate (response evaluation criteria in solid tumors).
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The potential existence of multiple different tests with 
different scoring systems will also be a recipe for confusion, 
among oncologists and pathologists alike. This could be com-
pounded by the need for different scoring systems in different 
tumor types, using the same antibody test. Experience tells us 
that where there is confusion, or complication in test assess-
ment, attitudes toward the test are changed. This has an impact 
on both the willingness of pathologists to provide the test and 
probably the quality of the data delivered from assessing 
the test staining. In large institutions where several of these 
drugs may be used, there could be significant logistical issues 
in terms of ensuring that the appropriate test is carried out. 
Unless an institution focuses on only one drug, or there is a 
level of communication between oncologist and pathologist 
that is, to date, unprecedented, it will be impossible to under-
take reflex testing for PD-L1 expression. There is a consider-
able danger that these issues could have a significant impact 
on an institution’s interest or ability to use these therapies.
Is there any possibility for test harmonization? The tra-
ditional model, prospectively proving a specific biomarker in 
a clinical trial, is well understood. Scientific rigor determines 
that any deviation from what was shown in the trial to be effec-
tive may lead to different and misleading results, a situation 
which is unacceptable when considering companion diagnos-
tics. Is there an opportunity to somehow determine equiva-
lence between a number of available diagnostic anti-PD-L1 
IHC antibodies? And if equivalent staining performance can 
be demonstrated, what are the chances of developing a stan-
dardized scoring system, across test platforms, that may be 
shown to be predictive for response to a number of these prom-
ising therapies? A concerted, multicenter, international effort 
could provide a mechanism to do such work, but this would 
require collaboration by both pharmaceutical and diagnostic 
companies with academic pathologists, to facilitate access to 
both the diagnostic tests and trial outcome data. Such a study 
could eventually also be extended to identify whether alter-
native biomarkers could either replace, or be combined with, 
PD-L1 as a predictive classifier, recognizing the complexity of 
the immune system.
QUESTIONS TO BE ADDRESSED
PD-L1 IHC seems to be an encouraging predictive bio-
marker for anti-PD-L1/PD-1 therapy in NSCLC, but given our 
current state of knowledge and understanding, the pursuit of 
a PD-L1 IHC assay as a “companion diagnostic” raises many 
issues. Questions still remain to be addressed regarding the 
biology of PD-L1 expression, including heterogeneity, cor-
relations with stage of disease, ethnical associations, demo-
graphic characteristics, impact of prior lines of therapy, and 
associated co-medications including steroids, mutation status 
of the tumor, and any prognostic effects. Our understanding of 
the prognostic significance of PD-L1 expression is not clear, 
yet this will have impact interpretation of biomarker-based 
treatment outcomes.22,23 These are important issues, if patients 
are to be appropriately selected for, or denied, a potentially 
effective treatment. In considering this effectiveness, most 
data refer to overall response rate, while progression-free and 
overall survival may be more valid measures, and we have 
yet to see prospective, randomized phase II or III trials com-
paring these immunotherapies with standard chemotherapy. 
Regarding the assay itself, the influences of preanalytical 
variables, applicability across different staining platforms, 
usage on different sample types (large tumor samples, small 
biopsies, and cytology), intralaboratory and interlaboratory 
reproducibility, intraobserver and interobserver variability, 
and epitope stability in stored materials are matters for further 
study.
PROPOSAL FOR MULTICENTRE 
INTERNATIONAL STANDARDIZATION PROJECT
A multicenter, international standardization effort could 
address many of these questions and help develop one “stan-
dardized” assay, for each of this family of drugs that comes 
into clinical use and analyze additional immunotherapy-
related predictive markers. Of course, these therapeutic agents 
are at different stages of development, and there is no guar-
antee that all of them will reach the market, but if more than 
one does, then the issues described above become highly rel-
evant, assuming the biomarker is required to select patients. 
Commercial considerations will undoubtedly be an issue 
in terms of what can be done. It will be a disservice to our 
patients, however, if the complications discussed in this review 
have impact upon the availability of a valuable treatment.
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